康莱特联合EPOCH方案治疗复发或难治性中高度恶性非霍奇金淋巴瘤的观察  

Clinical Observation of Kanglaite Injection Combined with EPOCH Regimen for Relapsed or Resistant Advanced non-Hodgkin's Lymphoma

作　　者：付晓瑞[1] 张紫娟[2] 孙振昌[1] 张明智[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州市450000 [2]河南省中医学院基础医学院,郑州市450000

出　　处：《医药论坛杂志》2010年第21期53-55,共3页Journal of Medical Forum

摘　　要：目的观察康莱特注射液联合EPOCH方案治疗复发或难治性中高度恶性非霍奇金淋巴瘤的疗效及不良反应。方法将经病理及免疫组织化学法确诊的复发或难治性中高度恶性非霍奇金淋巴瘤患者随机分为两组,对照组25例,采用EPOCH方案化疗;治疗组23例,化疗的同时加用康莱特注射液。结果治疗组的近期疗效(PR+CR)、消化道反应及血液学毒性分级情况均优于对照组(P<0.05),具有显著性差异。结论康莱特注射液联合化疗治疗非霍奇金淋巴瘤能提高治疗疗效,减轻化疗引起的不良反应,提高患者的生存质量。Objective To observe the curative effects and adverse reactions of Kanglaite Injection combined with EPOCH regimen on relapsed or resistant advanced non-Hodgkin＇s Lymphoma.Methods The relapsed or resistant advanced non-Hodgkin＇s Lymphoma patients confirmed by pathological and immunohistochemical method were randomly divided into two groups,the control group with 25 cases,using EPOCH regimen;the treatment group with 23 cases,chemotherapy with the Kanglaite Injection.Results The effective rate（CR＋PR）,digestive tract and adverse reaction in blood of the treated group are better than those of the control group,and the difference is significant.Conclusion The combination of KI with chemotherapy for treating non-Hodgkin＇s Lymphoma can heighten the curative effect of chemotherapy,reduce the toxic and side effects of chemotherapy,improve the quality of life.

关 键 词：非霍奇金淋巴瘤 康莱特 联合化疗 

分 类 号：R733.1[医药卫生—肿瘤]